《Myelodysplastic syndrome overview》專家PPT內(nèi)容預(yù)覽
（專家課件預(yù)覽：點(diǎn)擊下圖可進(jìn)行全文預(yù)覽）

《Myelodysplastic syndrome overview》專家PPT內(nèi)容簡介
    Myelodysplastic syndrome (MDS)
    It is a term for a heterogeneous collection of haemopoietic stem cell disorders affecting older adults.
    There is underlying ineffectiveness of haemopoiesis that results in dysplasia of bone marrow precursors and pe**heral cytopenias.
    Moderate anaemia is the most common clinical problem in MDS patients, but complete myeloid bone marrow failure also occurs leading to death from bleeding or infection.
    Approximately half of the patients transform to AML.
    Prognosis depends on the individual’s risk factors, with median survival ranging from 5.7 years in lower-risk group to 1.2 years or less in those with higher-risk MDS.
    MDS is extremely difficult to treat. Most cases are resistant to current therapies, and the most potent anti-MDS treatments (transplantation and dose intensive chemotherapy) are often too toxic for the majority of patients.

    MDS background   
    Pathobiology
    The cardinal features of MDS are 
    Increased marrow proliferation
    Failure of stem cells to differentiate
    And increased marrow apoptosis.
    The disease is of clonal origin
    Chromosomal abnormalities are detectable in 30-70% of patients. The no. of chromosomal abn. may correlate with the risk of progression to AML.

《Myelodysplastic syndrome overview》專家PPT完整版下載地址：